menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Novo Holdings joins €23M Series A for Tribune Therapeutics

    PR NEWSWIRE

    MUHC Foundation gets $2M for Metabolic Centre of Excellence

    GLOBENEWSWIRE

    Novo offers cheaper Wegovy for all cash-paying patients

    FIERCE PHARMA

    Novo licenses China-based biotech`s drug for up to $2B

    REUTERS

    United Labs, Novo Nordisk agree on UBT251 license deal

    GLOBENEWSWIRE

    Not a cost-cutting exercise`: Novo reshapes R&D setup

    FIERCE BIOTECH

    Novo Nordisk Foundation Project Sparks Ultra-Processed Food Debate

    REUTERS

    FDA to hold off action on weight-loss drug copies pending court ruling

    REUTERS

    Novo’s CagriSema Shows Superior Weight Loss In Redefine 2 Trial

    GLOBENEWSWIRE

    Novo trial with next-gen diabetes drug shows 15.7% weight loss

    REUTERS

    Novo to sell Wegovy for $499 a month to cash-paying US customers

    PR NEWSWIRE

    Novo Nordisk Launches "My Ozempic Era" Campaign For Patients

    PR NEWSWIRE

    Gensaic, Novo Nordisk Partner on Next-Gen Precision Therapies

    BUSINESSWIRE

    Novo Nordisk A/S: Annual General Meeting Notice

    GLOBENEWSWIRE

    Novo`s Wegovy and Ozempic removed from US FDA shortage list

    REUTERS

    FDA Confirms Wegovy & Ozempic Shortage Over, Novo Meets Demand

    PR NEWSWIRE

    Novo alleges fraud after $1.3 B deal to buy drug from KBP Biosciences

    FIERCE BIOTECH

    Novo Nordisk calls out dangers of compounded GLP-1s in new ad

    FIERCE PHARMA

    Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial

    BIOSPACE

    Novo Nordisk Board, Executives Trade Company Shares

    GLOBENEWSWIRE

    Trading in Novo shares by board members, executives associated persons

    GLOBENEWSWIRE

    Novo fails trial, linking obesity asset to psychiatric effects

    FIERCE BIOTECH

    Novo Nordisk Says Trump Tariffs May Have Limited Business Impact

    REUTERS

    Novo defends next-gen obesity drug CagriSema, details new trial

    REUTERS

    Novo Nordisk Sales Increased by 25% in 2024 to DKK 290.4 Billion

    GLOBENEWSWIRE

    Novo Nordisk files annual report with the SEC

    GLOBENEWSWIRE

    Wegovy maker Novo says surging growth driving emissions higher

    REUTERS

    Novo Nordisk A/S - share repurchase programme

    GLOBENEWSWIRE

    Investors answers on Novo Nordisk`s next-gen obesity drug CagriSema

    REUTERS

    Novo Nordisk To Test CagriSema`s Long-Term Efficacy In Trial

    REUTERS

    FDA approves Novo`s Ozempic to cut risk of diabetic kidney disease

    PRESS RELEASE

    Veru`s drug helps older obese patients on Wegovy preserve muscle

    REUTERS

    Novo to cap insulin prices in settlement; joins Lilly, Sanofi

    REUTERS

    Novo Nordisk A/S - share repurchase programme

    GLOBENEWSWIRE

    Moderna, Novo slammed for breaching UK drug marketing code again

    FIERCE PHARMA

    Novo`s amycretin prompts 22% weight loss in early obesity trial

    ENDPTS

    Novo inks IMMvention deal to orchestrate attack on sickle cell

    GLOBENEWSWIRE

    Study of Novo, Lilly weight loss drugs show decrease in Alzheimer`s

    FIERCE PHARMA

    Novo Nordisk A/S - share repurchase programme

    GLOBENEWSWIRE

    Novo touts weight loss results in high-dose Wegovy study

    FIERCE PHARMA

    Novo`s Ozempic, Wegovy picked for US Medicare price negotiations

    REUTERS

    Novo Nordisk: Semaglutide Shows 20.7% Weight Loss In Step up Trial

    GLOBENEWSWIRE

    Novo Nordisk A/S - share repurchase programme

    GLOBENEWSWIRE

    Novo Invests $200M for Windward Bio`s Asthma and COPD Treatments

    PR NEWSWIRE

    Novo Puts $4.6B on the Line to Expand Valo Deal

    BIOSPACE

    Wegovy and Zepbound tipped to fuel $20B heart failure boom

    FIERCE PHARMA

    Novo, Lilly launches top Clarivate`s `Drugs to Watch` list

    FIERCE PHARMA

    SomaScan Assay Drives Insights On Semaglutide Published In Nature

    GLOBENEWSWIRE

    Variant Bio, Novo Nordisk Partner On Metabolic Disease Research

    PR NEWSWIRE

    Novo petitions FDA over Victoza compounding as generic win approval

    FIERCE PHARMA

    Novo, Lilly poised to overcome GLP-1 supply constraints in 2025

    FIERCE PHARMA

    FDA approves Hikma`s generic of Novo`s diabetes drug Victoza

    REUTERS

    US FDA approves Novo Nordisk`s bleeding disorder drug

    REUTERS

    Novo stock crashes after CagriSema misses weight-loss goal

    FIERCE BIOTECH

    Novo to Explore CagriSema Weight-Loss Potential in New Trial

    REUTERS

    Zealand CEO: Novo`s CagriSema Data Supports Monotherapy Approach

    REUTERS

    Weight-Loss Drug Developers Eye $150 Billion Market

    REUTERS

    Novo and Lilly Face Growing Competition from Weight Loss Copies

    REUTERS

    Novo Nordisk A/S - share repurchase programme

    GLOBENEWSWIRE

    Novo Nordisk`s Biologic Alhemo Receives Approval in US

    FDA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.